Draft. Pending scientific and legal review. Not medical advice.
CardioGenomarkers: cardiology and metabolism
CardioGenomarkers groups genetic susceptibility panels for cardiomyopathies, arrhythmias and cardiometabolic disorders such as diabetes, obesity and hypertension. Narrower profiles also appear under genetic profiles. They do not replace clinical cardiology assessment.
What the catalogue covers
NGS panels include, among others, Brugada syndrome, hypertrophic cardiomyopathy, dilated cardiomyopathy, atrial fibrillation, cardiovascular risk, hypertension, diabetes and obesity, obesity and metabolic syndrome.
Genetic profiles include narrower versions for cardiovascular, obesity and metabolic-syndrome axes. Choosing profile versus panel depends on the clinical question set by the professional.
Cardiomyopathies, arrhythmias and metabolism
In practice the catalogue separates two kinds of question:
- Cardiomyopathies and arrhythmias with a more Mendelian or single-gene/panel hereditary component (Brugada syndrome, hypertrophic or dilated cardiomyopathy, atrial fibrillation). - Cardiometabolic traits with more complex architecture (cardiovascular risk, hypertension, diabetes and obesity, obesity, metabolic syndrome), where panels list associated variants and the catalogue complex-trait notice applies especially clearly.
Cardiovascular, obesity and metabolic-syndrome profiles offer narrower scope than their sibling panels. Specific priced tests are not promoted here; study types are named.
Prudent clinical use
These studies may inform hereditary susceptibility or genes linked to cardiometabolic phenotypes. They do not replace ECG, echocardiography, laboratory tests or the rest of the clinical work-up.
Cardiomyopathy variants are often interpreted with ACMG/AMP criteria and ClinGen curation. A variant of uncertain significance (VUS) is not a diagnosis. Communication to relatives and genetic counselling, when required, are organised by the clinical team.
Cautions
Associated-variant panels do not establish a diagnosis or an individual predictive value for complex traits (for example polygenic cardiovascular risk or obesity). Predisposition does not necessarily mean the disease will develop.
Pending Phase 0: operational data per study and verification of gene lists.
